Generics Approval, PTV News: Apr 08, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Generics Approval, PTV News: Apr 08, 2010
Released on: April 08, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Company
Teva gets thumbs up for versions of Merck and Co's Hyzaar and Cozaar
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Teva
Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company headquartered in Petah Tikva, Israel. It specializes in generic and proprietary pharmaceuticals and active pharmaceutical ingredients. It is among the largest generic drug manufacturers in the world and one of the 20 largest pharmaceutical companies worldwide.
Merck & Co.
Merck & Co., Inc., also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The headquarters of the company is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. It was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and set up as an independent company. It is currently one of the seven largest pharmaceutical companies in the world both by market capitalisation and revenue.

Merck's products cover a broad range of areas, including heart and respiratory health, infectious diseases, sun care and women’s health. And Merck focuses its research on conditions that affect millions of people around the world – diseases like Alzheimer’s, diabetes and cancer – while building strengths in new areas like biologics.